astra

British-Swedish drugmaker AstraZeneca has received approval from US Food and Drug Administration (FDA) for its once-daily Xigduo XR to treat adult patients with type 2 diabetes.

Xigduo XR is a combination of two anti-hyperglycaemic agents, Farxiga (dapagliflozin), an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, in a once-daily oral tablet.

AstraZeneca global medicines development head Elisabeth Björk said: “The addition of Xigduo XR to our US diabetes portfolio is further evidence of AstraZeneca’s commitment to develop new treatment options for patients with type 2 diabetes.

“The approval of once-daily Xigduo XR provides prescribers and adult patients with another treatment choice, supporting a more personalised approach to disease management.”

“The once-daily tablet is indicated as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.”

The once-daily tablet is indicated as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.

The drug already obtained approval in Australia to treat adults with type 2 diabetes, along with diet and exercise.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Xigduo (dapagliflozin and metformin hydrochloride), which uses an immediate-release form of metformin, has received European Union approval.

According to Astrazeneca, SGLT2 inhibitors are a new class of medicines that remove glucose from the body through the kidneys.

AstraZeneca develops and markets medicines for cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.


Image: AstraZeneca’s R&D site in Mölndal, Sweden. Photo: courtesy of Erik031.

Pharmaceutical Technology Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Pharmaceutical Technology Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now